Clinical Trial Update: JYP0322 Versus Platinum Based Doublet Chemotherapy in ROS1 Positive Patients Previously Treated With ROS1-TKIs. [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial comparison is planned between JYP0322 and platinum-based doublet chemotherapy in ROS1-positive non-small cell lung cancer patients who …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• JYP0322
• Platinum-based doublet chemotherapy

Snippet

Sponsor: Guangzhou JOYO Pharma Co., Ltd | Conditions: Non Small Cell Lung Cancer | Phase 3 | Status: NOT_YET_RECRUITING